IMRN
Immuron Limited
NASDAQ · Healthcare · Biotechnology · AU
$1.80
+62.16%Year over year
Reported trailing growth
- Revenue
- +28.7%
- EBITDA
- -3.0%
- EBIT
- +5.3%
- EPS
- +37.6%
- Free cash flow
- +35.0%
- Operating cash flow
- +35.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +61.1%
- EBITDA
- +12.7%
- EBIT
- +13.3%
- Net income
- +28.0%
- EPS
- +44.4%
- Free cash flow
- +51.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026